Pacer Advisors Inc. Has $10.33 Million Position in Boston Scientific Co. (NYSE:BSX)

Pacer Advisors Inc. increased its stake in shares of Boston Scientific Co. (NYSE:BSX) by 79.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 178,639 shares of the medical equipment provider’s stock after acquiring an additional 79,168 shares during the quarter. Pacer Advisors Inc.’s holdings in Boston Scientific were worth $10,327,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Bruce G. Allen Investments LLC bought a new stake in Boston Scientific in the fourth quarter valued at about $28,000. Sunbelt Securities Inc. acquired a new stake in Boston Scientific in the 1st quarter valued at about $32,000. Motco boosted its position in Boston Scientific by 136.3% during the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 372 shares during the period. Coppell Advisory Solutions LLC bought a new position in shares of Boston Scientific during the second quarter worth approximately $34,000. Finally, Acadian Asset Management LLC bought a new position in Boston Scientific during the first quarter worth about $35,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BSX shares. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $67.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Wells Fargo & Company raised their price target on shares of Boston Scientific from $70.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Morgan Stanley lifted their price target on Boston Scientific from $58.00 to $61.00 and gave the stock an “overweight” rating in a report on Monday, December 4th. Citigroup boosted their target price on shares of Boston Scientific from $65.00 to $71.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Finally, JPMorgan Chase & Co. boosted their target price on Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $66.62.

Insiders Place Their Bets

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 15,172 shares of Boston Scientific stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $59.25, for a total value of $898,941.00. Following the completion of the transaction, the executive vice president now directly owns 56,588 shares of the company’s stock, valued at approximately $3,352,839. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Jeffrey B. Mirviss sold 15,172 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $59.25, for a total value of $898,941.00. Following the sale, the executive vice president now owns 56,588 shares of the company’s stock, valued at $3,352,839. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $66.35, for a total transaction of $463,322.05. Following the transaction, the executive vice president now owns 53,788 shares in the company, valued at $3,568,833.80. The disclosure for this sale can be found here. Insiders have sold a total of 76,460 shares of company stock valued at $4,759,945 in the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 1.0 %

NYSE BSX opened at $68.62 on Thursday. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $65.24 and its 200 day moving average is $58.05. Boston Scientific Co. has a 12 month low of $48.10 and a 12 month high of $68.66. The stock has a market cap of $100.86 billion, a PE ratio of 64.13, a P/E/G ratio of 2.36 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. The firm had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. During the same quarter last year, the business posted $0.45 earnings per share. Research analysts predict that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.